Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population
NCT ID: NCT03434808
Last Updated: 2020-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
19 participants
INTERVENTIONAL
2017-01-13
2018-08-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
NCT00319657
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
NCT01852370
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00003538
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
NCT01050946
Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease
NCT00006417
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The iPS cells that are made as part of this study will be included in a bank owned by CDI. The iPS cells and the cells made from them will be available for laboratory research or for clinical use in patients. It is possible that the iPS cells made from the blood donated and cells made from the iPS cells could be beneficial to many different patients and be used for many different research projects to understand human biology and disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whole Blood Donation
Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Possess an HLA haplotype of interest to the Study
3. Be at least 18 years of age and not past 61st birthday
4. Meet the following criteria and requirements:
4.1 Meet the donor requirements under 21 CFR 1271 and related August 2007 guidance 4.2 Body weight of at least 110 pounds 4.3 Complete and pass the abbreviated Health History Screening questionnaire 4.4 Complete and pass the full Health History questionnaire after donor enrollment 4.5 Non-reactive for any FDA-listed relevant communicable disease agent 4.6 Non-reactive for cytomegalovirus (CMV) 4.7 Express blood group O
Exclusion Criteria
2. Be pregnant
3. Have a prior history of: (i) a bone marrow transplant, or (ii) cancer of any type
18 Years
61 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cellular Dynamics International, Inc. - A FUJIFILM Company
UNKNOWN
Center for International Blood and Marrow Transplant Research
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dennis Confer, MD
Role: PRINCIPAL_INVESTIGATOR
National Marrow Donor Program
Amanda Mack, PhD
Role: PRINCIPAL_INVESTIGATOR
Cellular Dynamics International, Inc. - A FUJIFILM Company
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-CDI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.